...
首页> 外文期刊>Trials >Efficacy and safety of gyejigachulbutang (Gui-Zhi-Jia-Shu-Fu-Tang, Keishikajutsubuto, TJ-18) for knee pain in patients with degenerative knee osteoarthritis: a randomized, placebo-controlled, patient and assessor blinded clinical trial
【24h】

Efficacy and safety of gyejigachulbutang (Gui-Zhi-Jia-Shu-Fu-Tang, Keishikajutsubuto, TJ-18) for knee pain in patients with degenerative knee osteoarthritis: a randomized, placebo-controlled, patient and assessor blinded clinical trial

机译:格吉加氯丁糖(Gui-Zhi-Jia-Shu-Fu-Tang,Keishikajutsubuto,TJ-18)对退行性膝骨关节炎患者膝关节疼痛的疗效和安全性:一项随机,安慰剂对照,患者和评估者为盲的临床试验

获取原文
           

摘要

Degenerative knee osteoarthritis is a leading cause of disability in the elderly. If patients do not respond to pharmacological or nonpharmacological intervention, total knee replacement surgery is recommended. However, owing to the contraindications and adverse effects of surgery, the need for a new treatment strategy is emerging. Traditional herbal medicine is a widely used intervention in east Asia to treat knee osteoarthritis. Gyejigachulbutang is one of the frequently prescribed herbal formulae. The aim of our study is to evaluate the efficacy and safety of gyejigachulbutang for knee osteoarthritis. This study is a randomized, placebo-controlled, patient and assessor blinded, superiority clinical trial. A total of 80 patients with knee osteoarthritis will be enrolled. The participants will be randomly assigned to the gyejigachulbutang or placebo group in a 1:1 ratio in two Korean medical hospitals. Every participant will take gyejigachulbutang or placebo at a dose of 2.5?g three times a day for 4?weeks. Additional follow-up will be conducted 4?weeks after treatment completion. Any concomitant treatment to relive knee pain will not be allowed except for rescue medicine (acetaminophen). The primary outcome will be a comparison of the change in the visual analogue scale score for knee pain from baseline to visit 3 (week 4) for both the treatment and placebo groups. Secondary outcomes include clinical relevance, minimal clinically important difference, disability, quality of life, and safety. This protocol presents a research methodology for clinical trials of gyejigachulbutang for knee osteoarthritis. Various secondary outcomes make this trial more informative. Our trial will provide fundamental evidence for knee osteoarthritis management via herbal medicine treatment. Clinical Research Information Service (CRIS), KCT0003024 . Registered on 25 July 2018.
机译:退行性膝骨关节炎是老年人残疾的主要原因。如果患者对药理或非药理干预没有反应,建议进行全膝关节置换手术。然而,由于手术的禁忌症和不良反应,对新治疗策略的需求正在出现。传统草药是东亚地区广泛使用的干预措施,以治疗膝盖骨关节炎。 Gyejigachulbutang是经常开出的草药配方之一。我们研究的目的是评估Gyejigachulbutang对膝部骨关节炎的疗效和安全性。这项研究是一项随机,安慰剂对照,对患者和评估者无视的优越性临床试验。总共将招募80名膝关节骨关节炎患者。参与者将按1:1的比例随机分配到两家韩国医疗医院的gyejigachulbutang或安慰剂组中。每位参与者每天服用2.5克gyejigachulbutang或安慰剂,每周3次,共4周。治疗结束后4周将进行其他随访。除急救药(对乙酰氨基酚)外,不允许采取任何伴随治疗来缓解膝关节疼痛。主要结果将是比较治疗组和安慰剂组从基线到就诊第3次(第4周)膝盖疼痛的视觉模拟量表评分的变化。次要结果包括临床相关性,最小的临床重要差异,残疾,生活质量和安全性。该协议提出了一种针对脑性骨关节炎的gyejigachulbutang临床试验的研究方法。各种次要结果使该试验更具参考价值。我们的试验将通过草药治疗为膝关节骨关节炎的治疗提供基础证据。临床研究信息服务(CRIS),KCT0003024。 2018年7月25日注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号